EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3)

A-M Arendt, F Heubach, C P Maier, S Giardino, G Jung, E Kowalewski, A Rabsteyn, G Amorelli, C Seitz, P Schlegel, R Handgretinger, P Lang

Cancer Immunology, Immunotherapy · 2023

DOI: 10.1007/s00262-023-03536-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2023. Verfasst von A-M Arendt und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Pediatrics, Oncology/Hematology, Children's University Hospital Tuebingen, Hoppe-Seyler-Str. 1, 72076, Tübingen, Germany. anne-…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neuroblastoma, Antibodies, Bispecific. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: iFIT excellence cluster, Deutsches Konsortium für Translationale Krebsforschung (DKTK) Heidelberg, Reinhold-Beitlich Stiftung Tuebingen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We investigated whether T cell-recruiting bispecific anti-CD3/GD2 antibody NG-CU might be an alternative to therapeutic anti-GD2 monoclonal antibody (mAb) ch14.18, mediating complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) through natural killer (NK) cells for immunotherapy in high-risk/relapsed neuroblastoma after autologous/allogeneic stem cell transplantation (auto/alloSCT). Different antibody concentrations and effector-to-target ratios ( E:T ) were evaluated using xCELLigence RTCA system, peripheral blood mononuclear cells (PBMCs) (healthy donors and patients after alloSCT), and neuroblastoma cell lines (LS/LAN-1). Mean specific lysis of LS cells utilizing PBMCs from healthy donors and ch14.18 (1 µg/ml) was 40/66/75% after 12/24/48 h compared to 66/93/100% in the presence of NG-CU (100 ng/ml). NG-CU showed enhanced cytotoxicity compared to ch14.18, even at lower concentrations and E : T ratios, and completely eradicated LS cells after 72 h. To decipher the influence of effector cell subsets on lysis, different ratios of T and NK cells were tested. At a ratio of 1:1, ch14.18 was more effective than NG-CU. Using patient PBMCs taken at different time points posttransplant, significant lysis with both constructs was detectable depending on percentages and total numbers of T and NK cells; in the early posttransplant phase, NK cells were predominant and ch14.18 was superior, whereas later on, T cells represented the majority of immune cells and NG-CU was more effective. Our study highlights the importance of analyzing effector cell subsets in patients before initiating antibody-based therapy. Consequently, we propose an adjusted administration of both antibody constructs, considering the state of posttransplant immune recovery, to optimize anti-tumor activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeuroblastomaAntibodies, BispecificHumansLeukocytes, MononuclearAntibodies, MonoclonalAntibody-Dependent Cell CytotoxicityGangliosides

Stichwörter der Autor:innen

Antibody-based therapiesGD2 antibodiesNeuroblastomaStem cell transplantation

Substanzen

dinutuximabAntibodies, MonoclonalAntineoplastic AgentsAntibodies, BispecificGangliosides

Autor:innen und Institutionen

  • Department of General Pediatrics, Oncology/Hematology, Children's University Hospital Tuebingen, Hoppe-Seyler-Str. 1, 72076, Tübingen, Germany. anne-marie.arendt@med.uni-tuebingen.de.
  • Department of General Pediatrics, Oncology/Hematology, Children's University Hospital Tuebingen, Hoppe-Seyler-Str. 1, 72076, Tübingen, Germany.
  • Department of Hematology/Oncology, Center for Internal Medicine, University Hospital, Tübingen, Germany.
  • Hematopoietic Stem Cell Transplantation Unit, Department of Hematology and Oncology, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • Interfaculty Institute for Cell Biology, Department of Immunology, Eberhard Karls University Tuebingen, Tübingen, Germany.

Förderung

  • iFIT excellence cluster
  • Deutsches Konsortium für Translationale Krebsforschung (DKTK) Heidelberg
  • Reinhold-Beitlich Stiftung Tuebingen
  • Wilhelm Sander-Stiftung Munich
  • Förderverein and Stiftung Krebskranke Kinder Tuebingen e.V
  • Universitätsklinikum Tübingen

Zitieren

APA

Arendt, A. M., Heubach, F., Maier, C. P., Giardino, S., Jung, G., Kowalewski, E., Rabsteyn, A., Amorelli, G., Seitz, C., Schlegel, P., Handgretinger, R., & Lang, P. (2023). Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3). Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-023-03536-x

Vancouver

Arendt AM, Heubach F, Maier CP, Giardino S, Jung G, Kowalewski E, et al. Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3). Cancer Immunology, Immunotherapy. 2023. doi:10.1007/s00262-023-03536-x

BibTeX
@article{Arendt2023,
  author = {Arendt, A-M and Heubach, F and Maier, C P and Giardino, S and Jung, G and Kowalewski, E and Rabsteyn, A and Amorelli, G and Seitz, C and Schlegel, P and Handgretinger, R and Lang, P},
  title = {Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3)},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2023},
  doi = {10.1007/s00262-023-03536-x}
}
Kostenlos starten →